📰 Valency Communications News
Page 2 - Valency Communications News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Valency Communications. Real-time updates on events, politics, business and more.
June 8, 2023
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announces that it has entered into a manufacturing alliance with NorthX Biologics AB . NorthX is a... | June 8, 2023
May 25, 2023
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation...
May 12, 2023
At the annual general meeting of Mendus AB , reg. no. 556629-1786, on 12 May 2023 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the... | May 12, 2023
May 11, 2023
MENDUS TO PRESENT UPDATES ON IMMUNOMONITORING DATA FROM ADVANCE II TRIAL AND PROGRESS ON THE DEVELOPMENT OF ITS NK CELL THERAPY PROGRAM Mendus AB , a biopharmaceutical company focused on... | May 11, 2023
April 19, 2023
VIDIDENCEL INDUCES DURABLE VACCINE-INDUCED T-CELL RESPONSES IN THE MAJORITY OF PATIENTS Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today... | April 19, 2023
April 6, 2023
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that the Company has agreed with Negma Group Ltd to redeem the remainder of the first... | April 6, 2023
April 4, 2023
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group has by notice to Mendus requested the conversion of convertible... | April 4, 2023
March 31, 2023
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group has by notice to Mendus requested the conversion of convertible bonds... | March 31, 2023
March 31, 2023
During March, the number of shares and votes in Mendus AB (publ) has changed as a result of 1,137,790 new shares being issued to Negma Group upon...
March 30, 2023
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group has by notice to Mendus requested the conversion of convertible bonds... | March 30, 2023